Results 101 to 110 of about 209,258 (305)

Exploring the role of mTOR pathway in aging and age-related disorders

EXCLI Journal : Experimental and Clinical Sciences
Aging is a highly intricate biochemical process. There is strong evidence suggesting that organismal aging, age-dependent diseases, and cellular senescence are related to the mammalian target of rapamycin (mTOR) signaling pathway.
Komal Raghuvanshi, Disha Raghuvanshi, Dinesh Kumar, Eugenie Nepovimova, Marian Valko, Kamil Kuca, Rachna Verma   +6 more
doaj   +1 more source

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

Molecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta, Yang Song, Madeleine Ndahayo, Anirudh Saxena, Theresa Guo, Dylan Z. Kelley, Jessica Gore, Andrew Hennigan, Alexa Anderson, John C. Papadimitriou, Daria A. Gaykalova   +10 more
wiley   +1 more source

Is Early Conversion to mTOR Inhibitors Represent a Suitable Choice in Renal Transplant Recipients? A Systemic Review of Medium-term Outcomes

International Journal of Organ Transplantation Medicine, 2017
Background: Immunosuppressive therapies are important parts of renal transplantation. Objective: To assess the present literature on the effectiveness of early introduction of mTOR inhibitors with or without calcineurin inhibitors (CNI) in renal ...
J Kumar, I Reccia, T Kussano
doaj  

Tumor-stroma interactions influence the response to PI3K targeted agents in preclinical models of colorectal cancer (CRC) [PDF]

, 2019
Introduction: One of the main obstacle to the successful development of therapeutic strategies remains the identification of biomarker underlying drug resistance. Recently, investigators have become more aware the role of the tumor microenvironment (TME)
Bazzichetto, Chiara
core  

The aberrant expression of the mesenchymal variant of FGFR2 in the epithelial context inhibits autophagy [PDF]

, 2019
Signaling of the epithelial splice variant of fibroblast growth factor receptor 2 (FGFR2b) triggers both differentiation and autophagy, while the aberrant expression of the mesenchymal FGFR2c isoform in epithelial cells induces impaired differentiation ...
Belleudi, Francesca, Nanni, Monica, Persechino, Flavia, Ranieri, Danilo, Torrisi, Maria Rosaria   +4 more
core   +1 more source

Development of ATP-Competitive mTOR Inhibitors [PDF]

, 2011
The mammalian Target of Rapamycin (mTOR)-mediated signaling transduction pathway has been observed to be deregulated in a wide variety of cancer and metabolic diseases. Despite extensive clinical development efforts, the well-known allosteric mTOR inhibitor rapamycin and structurally related rapalogs have failed to show significant single-agent ...
Qingsong, Liu, Seong A, Kang, Carson C, Thoreen, Wooyoung, Hur, Jinhua, Wang, Jae Won, Chang, Andrew, Markhard, Jianming, Zhang, Taebo, Sim, David M, Sabatini, Nathanael S, Gray   +10 more
openaire   +2 more sources

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

Molecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

The role of phospholipase D in modulating the MTOR signaling pathway in polycystic kidney disease.

PLoS ONE, 2013
The mammalian target of rapamycin (mTOR) signaling pathway is aberrantly activated in polycystic kidney disease (PKD). Emerging evidence suggests that phospholipase D (PLD) and its product phosphatidic acid (PA) regulate mTOR activity.
Yang Liu, Andres Käch, Urs Ziegler, Albert C M Ong, Darren P Wallace, Alexandre Arcaro, Andreas L Serra   +6 more
doaj   +1 more source

mTOR Pathway and mTOR Inhibitors in Cancer Therapy [PDF]

British Journal of Clinical Pharmacology, 2011
The latest in the series of monographs Cancer Drug Discovery and Development is mTOR Pathway and mTOR Inhibitors in Cancer Therapy. Rapamycin was first employed as an antifungal agent in humans and named for the Polynesians (Papa Nui) who inhabited Easter Island, where it was isolated from the bacteria Streptomyces hygroscopidcus.
openaire   +1 more source

Basroparib inhibits YAP‐driven cancers by stabilizing angiomotin

Molecular Oncology, EarlyView.
Basroparib, a selective tankyrase inhibitor, suppresses Wnt signaling and attenuates YAP‐driven oncogenic programs by stabilizing angiomotin. It promotes AMOT–YAP complex formation, enforces cytoplasmic YAP sequestration, inhibits YAP/TEAD transcription, and sensitizes YAP‐active cancers, including KRAS‐mutant colorectal cancer, to MEK inhibition.
Young‐Ju Kwon, Dong Young Kim, Yuna Kim, Uk‐Il Kim, Jae‐Sung Kim   +4 more
wiley   +1 more source